Innoviva, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
SAVACassava Sciences, Inc. -2.41%43.410.0%$446.90m
GWPHGW Pharmaceuticals Plc 0.36%214.946.1%$304.66m
VRXValeant Pharmaceuticals International, Inc. 3.39%32.9814.1%$194.06m
HZNPHorizon Therapeutics Plc 2.85%88.655.5%$177.01m
JAZZJazz Pharmaceuticals Plc 2.68%164.752.3%$175.22m
BHCBausch Health Cos., Inc. 3.39%32.980.0%$159.43m
ICLRICON plc 4.55%179.834.2%$117.77m
CTLTCatalent, Inc. 1.33%104.452.1%$101.54m
PRGOPerrigo Co. Plc 1.31%41.106.9%$81.49m
TNXPTonix Pharmaceuticals Holding Corp. 5.37%1.020.2%$59.35m
ARGXargenx SE -0.53%289.750.0%$57.97m
UTHRUnited Therapeutics Corp. 2.50%164.3414.1%$47.27m
ZYNEZynerba Pharmaceuticals, Inc. 1.47%4.156.0%$44.31m
AMRNAmarin Corp. Plc 4.72%5.991.5%$39.46m
RVMDRevolution Medicines, Inc. 7.19%45.500.0%$37.56m

Company Profile

Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.